National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 5) (PB 55 of 2019) (Cth)

PB 55 of 2019

National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 5)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated   27 June 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 5).

(2)This Instrument may also be cited as PB 55 of 2019.

1. Commencement

This Instrument commences on 1 July 2019.

1. Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1 Amendments

1. Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 54 mg (extended release)

insert:

Capsule containing methylphenidate hydrochloride 10 mg (modified release)

1. Schedule 4, omit entry for Amino acid formula with fat, carbohydrate, without phenylalanine 

1. Schedule 4, entry for Amoxicillin with clavulanic acid

substitute:

Amoxicillin with clavulanic acid	Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL
Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL